Site Maintenance October 29 – November 5
SCCM is currently performing major updates to its digital infrastructure to better serve members. Any website that requires an SCCM Customer ID and password to log in is currently unavailable until November 5, 2024. SCCM Customer Service and staff have limited capabilities, and response times will be longer during this time.

 

SCCM Pod-374 Angiotensin II Treatment in Patients with Vasodilatory Shock and Renal Replacement Ther

visual bubble
visual bubble
visual bubble
visual bubble
12/10/2018

 

Todd Fraser, MD, speaks with Rinaldo Bellomo, MD, MBBS, FRACP, FCICM, FAAHMS, about the article "Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II" (Tumlin JA, et al. Crit Care Med. 2018;46:949-957).

Dr. Bellomo discusses his post-talk analysis of the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) trial and potential benefits of angiotensin II in patients with shock requiring renal replacement therapy. Dr. Bellomo is the director of intensive care research at Austin Hospital in Melbourne, Australia.

*If you are unable to play the podcast please click here to download the file.

Disclaimer

 

Knowledge Area:

Recent Podcasts

^